Matt M. Mauney

Matt Mauney is a partner in Goodwin’s Private Equity group. He advises public and private companies as well as private equity and venture capital firms on a wide array of complex business transactions, including structuring and negotiating strategic and leveraged acquisitions and divestitures, mergers and acquisitions, cross-border transactions, venture capital and growth equity investments, equity and debt financings, recapitalizations and restructurings, executive compensation and incentive equity matters, and general corporate counseling and compliance. Matt has worked with both middle-market and upmarket clients on transactions ranging in size from several million dollars to billions of dollars. He has extensive experience working in a variety of industries, including regulated industries such as healthcare and banking.

Prior to joining Goodwin in 2019, Matt was a partner at Kirkland & Ellis LLP.

Matt’s experience includes representing:

• Novo Holdings in its pending $16.5 billion take-private of Catalent Inc. (NYSE: CTLT)
• TA Associates in its $2.5 billion acquisition of Veracode
• Arlington Capital Partners in its acquisition of Afton Scientific Properties, L.L.C.
• Arlington Capital Partners in its acquisition of Integrated Data Services
• TA Associates in its $1.6 billion acquisition of Planview alongside TPG from Thoma Bravo
• The Halifax Group in its acquisition of Milestone Technologies, Inc.
• The Halifax Group in its acquisition of 101 Mobility
• Novo Holdings in its acquisition of KabaFusion
• Arlington Capital Partners in its acquisition of the Avian Vaccine Services business of Charles River Laboratories
• Peleton in its $2 billion sale of Aerocare to AdaptHealth Corp. (NASDAQ: AHCO)The Halifax Group in its acquisition of Milestone Technologies, Inc.
• Novo Holdings in its $462 million investment in Paratek Pharmaceuticals Inc.
• Cast & Crew in its acquisition of Backstage Holdings
• Lime Rock New Energy in its investment in Electric Power Engineers
• The Halifax Group in its investment in Case Facilities Management Solutions
• Novo Holdings in its acquisition of Ritedose Corporation from AGIC Capital and Humanwell
• Backstage in its acquisitions of FilmFreeway, Coverfly, Voice 123, StarNow and The Mandy Network
• Novo Holdings in its purchase of a minority stake in Availity from Francisco Partners
• TA Associates in its sale of CCRM Fertility to Atlas, Ares and Oak HC/FT via Unified Women’s Healthcare 
• TA Associates in its $130 million strategic investment in Stackline
• TA Associates in its strategic investment in Death Wish Coffee
• Novo Holdings in its acquisition of Altasciences
• TA Associates in its investment in Backstage
• The Halifax Group in its investment in Prairie Industries and Nu-Pak
• Lime Rock New Energy in its investment in Smart Wires
• Lime Rock New Energy in its investment in Qmerit
• ArisGlobal in its sale to European buyout firm, Nordic Capital, for a reported purchase price of over $700 million
• TA Associates in its investment alongside Clearlake Capital Group, L.P. in DigiCert, Inc.
• Madison Dearborn Partners in its acquisition of Solis Mammography*
• Salient Partners in the sale of its Salient Private Client business, with $4.5 billion in assets under management*
• Family Health Network in the sale of its Medicaid business to two purchasers*
• Summit Partners in its purchase of $150 million of senior secured debt capital from NCB Management Services Inc.*
• Summit Partners in its investment in Uber*
• Madison Dearborn Partners in its $6.4 billion sale of VWR Corp. to Avantor*
• Madison Dearborn Partners and Patterson Medical in the acquisition of Performance Health*
• Madison Dearborn Partners in its $2.77 billion sale of Sage Products LLC to Stryker Corporation*
• Madison Dearborn Partners in its $2.3 billion sale of Ikaria, Inc. to Mallinckrodt plc.*
• Madison Dearborn Partners in its $715 million acquisition of Patterson Medical Inc.*
• Thoma Bravo in its $930 million acquisition of TravelClick*
• Summit Partners in its sale of National Veterinary Associates for over $800 million*
• GTCR in its acquisition of XIFIN Inc.*
• Pine Brook Road Partners in its $110 million line of equity investment in Strategic Funding Source Inc.*
• Centene Corporation in its $152 million purchase of AcariaHealth, a specialty pharmacy business*
• Sumitomo in its acquisition of a 50 percent interest in the Ironwood and Cimarron II wind projects from Duke Energy Renewables*
• Constellation in its $7.9 billion merger with Exelon*
• NRG in its sale to MidAmerican Energy Holdings Company of a 49 percent interest in the Agua Caliente solar project (which was named Solar Project of the Year by Renewable Energy World)*

*Denotes experience prior to joining Goodwin

• Co-Author, “Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure,” Annals of Human Genetics 70(Pt 1):27-41, 2006
• Co-Author, “Variants associated with common disease are not unusually differentiated in frequency across populations,” American Journal of Human Genetics 78(1):130-6, 2006